AR-V7 expression facilitates accelerated G2/M phase transition in castration-resistant prostate cancer

Taruna Saini1, Parth Gupta1, Rajnikant Raut1

  • 1Department of Biotechnology, Indian Institute of Technology Hyderabad, Kandi, Sangareddy, 502284, India.

PubMed

Insights

Androgen receptor variant 7 (AR-V7) expression fluctuates during the cell cycle, peaking in G2/M phase. The CLK1-pSRSF1 pathway critically regulates AR-V7 generation in castration resistant prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Androgen deprivation therapy (ADT) resistance in prostate cancer is often driven by the emergence of the AR-V7 splice variant.
  • Understanding the regulation of AR-V7 is crucial for developing effective therapeutic strategies against castration resistant prostate cancer (CRPC).

Purpose of the Study:

  • To investigate the cell cycle-dependent regulation of AR-V7 expression.
  • To identify key molecular players involved in AR-V7 generation during the cell cycle.

Main Methods:

  • Cell cycle analysis using flow cytometry.
  • Western blotting to detect protein levels of AR-V7, CLK1, and p-SRSF1.
  • Knockdown and overexpression experiments of CLK1 in CRPC cells.

Main Results:

  • AR-V7 expression exhibits periodic fluctuations, peaking during the G2/M phase of the cell cycle.
  • CLK1 and phosphorylated SRSF1 (p-SRSF1) expression correlate with AR-V7 levels during specific cell cycle phases.
  • CLK1 activity is essential for modulating AR-V7 levels, with kinase-deficient mutants reducing AR-V7 expression.

Conclusions:

  • AR-V7 expression is periodically regulated throughout the cell cycle.
  • The CLK1-pSRSF1 axis plays a critical role in the generation of AR-V7.
  • Targeting CLK1 activity may offer a novel therapeutic approach for CRPC by modulating AR-V7 expression.

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.2K